Xifatre 550 Tablet contains Rifaximin 550 mg, a broad-spectrum, non-systemic antibiotic primarily used to treat gastrointestinal infections caused by susceptible bacteria. Rifaximin acts by inhibiting bacterial RNA synthesis through binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, resulting in bactericidal activity. Due to its minimal systemic absorption, Xifatre 550 is effective in targeting infections localized within the gastrointestinal tract with reduced systemic side effects. It is commonly prescribed for the treatment of travelers’ diarrhea caused by non-invasive strains of Escherichia coli, hepatic encephalopathy to reduce the risk of recurrent episodes by decreasing ammonia-producing gut bacteria, and irritable bowel syndrome with diarrhea (IBS-D) to alleviate symptoms. The recommended dosage and duration of therapy depend on the indication and patient-specific factors. Xifatre 550 should be used cautiously in patients with hypersensitivity to rifamycins and is contraindicated in individuals with severe liver impairment. Adverse effects are generally mild and may include nausea, abdominal pain, and headache. As with all antibiotics, it is important to complete the prescribed course to prevent the development of resistant bacterial strains. Consultation with a healthcare professional is advised before initiating therapy with Xifatre 550.